Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 24, Issue 3, 2012, Pages 349-353

  Karaiskos, Dimitrios ^a   Tzavellas, Elias ^a   Spengos, Konstantinos ^a   Vassilopoulou, Sofia ^a   Paparrigopoulos, Thomas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; SERTRALINE;

ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; POSTSTROKE DEPRESSION; PRIORITY JOURNAL; REMISSION; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 84867550690     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.11110325     Document Type: Article

References (33)

1. Sarti C, Rastenyte D, Cepaitis Z, et al: International trends in mortality from stroke, 1968 to 1994. Stroke 2000; 31:1588-1601
2. Gainotti G, Marra C: Determinants and consequences of poststroke depression. Curr Opin Neurol 2002; 15:85-89
3. Chemerinski E, Robinson RG, Arndt S, et al: The effect of remission of poststroke depression on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 2001; 189:421-425
4. Schwartz JA, Speed NM, Brunberg JA, et al: Depression in stroke rehabilitation. Biol Psychiatry 1993; 33:694-699
5. Williams LS, Ghose SS, Swindle RW: Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry 2004; 161:1090-1095
6. Barker-Collo SL: Depression and anxiety 3 months post stroke: prevalence and correlates. Arch Clin Neuropsychol 2007; 22: 519-531
7. Robinson RG: Mechanism and treatment of poststroke anxiety disorder in The Clinical Neuropsychiatry of Stroke Cognitive, Behavioral and Emotional Disorders Following Vascular Brain Injury. London, U.K., Cambridge University Press, 1998, pp 347-354
8. Winward C, Sackley C, Metha Z, et al: A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke 2009; 40:757-761
9. van der Werf SP, van den Broek HL, AntenHW, et al: Experience of severe fatigue long after stroke and its relation to depressive symptoms and disease characteristics. Eur Neurol 2001; 45:28-33
10. Chen Y, Guo JJ, Zhan S, et al: Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 2006; 40:2115-2122
11. Gainotti G, Antonucci G, Marra C, et al: Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 2001; 71:258-261
12. Starkstein SE, Mizrahi R, Power BD: Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother 2008; 9:1291-1298
13. Paolucci S: Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat 2008; 4:145-154
14. Rankin J: Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J 1957; 2:200-215
15. Krupp LB, LaRocca NG, Muir-Nash J, et al: The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46:1121-1123
16. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al: General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992; 12:3-10
17. Hackett ML, Anderson CS, House AO: Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005; 36:1098-1103
18. Wise TN, Wiltse CG, Iosifescu DV, et al: The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 2007; 61: 1283-1293
19. Brannan SK, Mallinckrodt CH, Brown EB, et al: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39:43-53
20. Szegedi A, Jansen WT, van Willigenburg AP, et al: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6,562 patients. J Clin Psychiatry 2009; 70:344-353
21. Papakostas GI, Thase ME, Fava M, et al: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? a meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62:1217-1227
22. Cipriani A, Furukawa TA, Salanti G, et al: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746-758
23. Fava M, Mallinckrodt CH, Detke MJ, et al: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65:521-530
24. Hartford JT, Endicott J, Kornstein SG, et al: Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry 2008; 10:197-204
25. Robinson RG, Spalletta G: Poststroke depression: a review. Can J Psychiatry 2010; 55:341-349
26. Spalletta G, Bossù P, Ciaramella A, et al: The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11:984-991
27. De Wit L, Putman K, Baert I, et al: Anxiety and depression in the first six months after stroke: a longitudinal multicentre study. Disabil Rehabil 2008; 30:1858-1866
28. Troisi E, Paolucci S, Silvestrini M, et al: Prognostic factors in stroke rehabilitation: the possible role of pharmacological treatment. Acta Neurol Scand 2002; 105:100-106
29. Trivedi MH, Desaiah D, Ossanna MJ, et al: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008; 23:161-169
30. Iyengar S, Webster AA, Hemrick-Luecke SK, et al: Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004; 311:576-584
31. Ingles JL, Eskes GA, Phillips SJ: Fatigue after stroke. Arch Phys Med Rehabil 1999; 80:173-178
32. Barker-Collo S, Feigin VL, Dudley M: Poststroke fatigue: where is the evidence to guide practice? N Z Med J 2007; 120:U2780
33. Duloxetine: new indication: depression and diabetic neuropathy: too many adverse effects. PMID: 17121211 Prescrire Int 2006; 15:168-172